Day: May 10, 2024

AEHL Records 78% Revenue Growth in 2nd Year of Operating its Livestreaming Ecommerce Business NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which operates KylinCloud, a livestreaming ecommerce business in China with access to 800,000+ hosts and influencers, today announced its financial results for the second half and fiscal year ended December 31, 2023. Fiscal Year 2023 SummaryRevenue was RMB 510.5 million (US$ 72.1 million), a 78.3% increase as compared to RMB 286.3 million (US$ 42.6 million) for fiscal year 2022. Gross profit was RMB 53.1 million (US$ 7.5 million), 90.0% increase as compared to RMB 27.9 million (US$ 4.1 million) for fiscal 2022. Net loss was RMB 14.5 million (US$ 2.0 million), as compared to a net...

All amounts in U.S. dollars unless otherwise stated TORONTO, May 10, 2024 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2024. “Onex is making progress in its plans to drive growth in shareholder value, and we were pleased to see fundraising start to gain momentum in the quarter,” said Bobby Le Blanc, Chief Executive Officer. “We continue to focus our capital deployment and resource allocation on areas where we have a proven track record and the right to compete.” Financial Results(unaudited, $ millions except per share amounts) Three Months Ended March 31    2024   2023  Net earnings (loss) $ 10   $ (232 )Net earnings (loss) per diluted share $ 0.13   $ (2.87 )         Investing segment net earnings $ 54   $ 44  Asset management segment...

Management to host conference call and webcast at 8:30am ET PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET.Live Conference Call & Webcast:Toll Free:   877-407-3982International:   201-493-6780Conference ID:   13746389Call...

DALLAS, May 10, 2024 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent Highlights:With successful completion of feasibility studies, preparations are underway with collaborator for a potential investigator-initiated trial (IIT) in non-small cell lung cancer with folate receptor α (FRα)-CoStAR TIL Exploring opportunities to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need Cash runway expected beyond 2026First Quarter 2024 Financial and Operating Results: As of March 31, 2024, Instil had cash, cash equivalents, marketable securities and long-term investments of $161.5 million,...

ORLANDO, Fla., May 10, 2024 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American LLC: GENC) announced today net revenues increased 33.4% to $40,676,000 for the quarter ended March 31, 2024 compared with $30,501,000 for the quarter ended March 31, 2023. Gross profit margins for the quarter ended March 31, 2024 were 30.3% compared with 29.8% for the quarter ended March 31, 2023 on improved absorption on increased production and favorable price realization. Product engineering and development expenses increased $19,000 to $893,000 for the quarter ended March 31, 2024, as compared to $874,000 for the quarter ended March 31, 2023. Selling, general and administrative (“SG&A”) expenses increased $1,295,000 to $4,357,000 for the quarter ended March 31, 2024, compared to $3,062,000 for the quarter ended...

NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (NASDAQ: AMCX) today reported financial results for the first quarter ended March 31, 2024. Chief Executive Officer Kristin Dolan said: “In the first quarter, we continued to execute on our strategic priorities, including the ongoing delivery of healthy free cash flow. As new technologies transform the way media is consumed, we continue to produce great content and make it available to viewers whenever and wherever they want to watch. We recently strengthened our balance sheet by completing a series of financing transactions that meaningfully extended our debt maturities. This creates substantial flexibility for us as we continue to leverage our core strengths and reorient our business around the consumer-driven...

MISSISSAUGA, Ontario, May 10, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the first quarter ended March 31, 2024. “In 2024, we intend to: (1) demonstrate our system at a customer site, (2) further improve our energy efficiency to exceed US DOE 2026 targets to world class efficiency levels, (3) complete pilot scale testing of our large-scale product line (up to 8MW per module) targeting large scale 100MW+ solutions, and (4) double our growing backlog,” said Raveel Afzaal, President & CEO. “We are progressing well on all of these goals with a fully financed business plan for 2024 and looking forward to a transformative year. We were honored by a visit by our Deputy Prime...

Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024 On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024 Strengthened leadership team with appointment of two key hires across Clinical and Technical Operations Ended the first quarter with $329 million in cash and cash equivalents and marketable securities, supporting operating plans into Q4 2025WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney”...

– Company to Host Webcast and Conference Call – BRANFORD, Conn., May 10, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the first quarter ended March 31, 2024. The Company will host a conference call on Friday, May 10, 2024 at 8:00 a.m. Eastern Time to discuss its financial and operating results. John Villano, CPA, Sachem Capital’s Chief Executive Officer, stated: “In the first quarter, we continued to navigate through an evolving and challenging macro environment marked by uncertainty regarding inflation, and the Federal Reserve’s future rate policy. We remain disciplined, and while long-term capital remains relatively unavailable to our borrowers, we are focused on maintaining strong liquidity, growing borrower relationships, and protecting our capital. Our diversified...